Who is sponsoring NCT04309825?

NCT04309825 is sponsored by Yale University.

What drugs are being tested in NCT04309825?

Interventions in NCT04309825: transgastrostomal endoscopy.

What condition does NCT04309825 study?

NCT04309825 studies Esophagogastroduodenoscopies.

Is NCT04309825 still recruiting?

NCT04309825 is currently withdrawn. Last updated 11 December 2020.

Last reviewed 2020-12-11 · How we verify

NCT04309825

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transgastrostomal Endoscopies

Withdrawn NA Last updated 11 December 2020

What this trial tests

NA trial testing transgastrostomal endoscopy in Esophagogastroduodenoscopies. Withdrawn.

Timeline

1 December 2021

Primary endpoint
1 April 2025

1 April 2025

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Start date	1 December 2021
Primary completion	1 April 2025
Estimated completion	1 April 2025
Sites	1 location across United States

Drugs / interventions tested

transgastrostomal endoscopy

Conditions studied

Esophagogastroduodenoscopies — all drugs for Esophagogastroduodenoscopies →

Sponsor

Yale University

Who can join

Adults 30 Days to 18, any sex, with Esophagogastroduodenoscopies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Upper GI endoscopies are commonly done by inserting the endoscope through the patient's mouth. When a patient has a gastrostomy feeding tube, the endoscope can be inserted through the stomach port opening. The aim is to prove this modification would lead to various health benefits, including need for lighter anesthesia, rapid recovery time and fewer anesthesia related adverse reactions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04309825 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 11 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04309825.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing